Multiple sclerosis and related disorders · 2026
Appendicitis and multiple sclerosis disease-modifying therapies: a disproportionality analysis of the FDA adverse event reporting system.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Balshi Alexandra, Esser Madelyn, Dempsey John P, Baber Ursela, Sloane Jacob A
Аннотация
BACKGROUND: Although appendicitis is one of the most common surgical emergencies and is related to immune function, its relation to multiple sclerosis (MS) disease-modifying therapies (DMTs) is unclear.
OBJECTIVE: To determine which, if any, MS DMTs are associated with disproportionally high appendicitis reporting using real-world data from the FDA Adverse Event Reporting System (FAERS).
RESULTS: We identified 965 reports of appendicitis associated with MS DMTs. A pooled analysis of all DMTs showed disproportionately high appendicitis reporting compared to all other FAERS medications (reporting odds ratio, 2.83; 95% confidence interval, 2.63-3.06; χ (Bhangu et al., 2015), 787.54). Ocrelizumab, ofatumumab, natalizumab, alemtuzumab, dimethyl and diroximel fumarate, cladribine, and peg- and interferon beta-1a all individually exhibited disproportionally high appendicitis reporting.
CONCLUSION: Patient counseling on early appendicitis warning signs and indications for urgent evaluation may be warranted for people with MS on DMTs.
OBJECTIVE: To determine which, if any, MS DMTs are associated with disproportionally high appendicitis reporting using real-world data from the FDA Adverse Event Reporting System (FAERS).
RESULTS: We identified 965 reports of appendicitis associated with MS DMTs. A pooled analysis of all DMTs showed disproportionately high appendicitis reporting compared to all other FAERS medications (reporting odds ratio, 2.83; 95% confidence interval, 2.63-3.06; χ (Bhangu et al., 2015), 787.54). Ocrelizumab, ofatumumab, natalizumab, alemtuzumab, dimethyl and diroximel fumarate, cladribine, and peg- and interferon beta-1a all individually exhibited disproportionally high appendicitis reporting.
CONCLUSION: Patient counseling on early appendicitis warning signs and indications for urgent evaluation may be warranted for people with MS on DMTs.